## Supplemental material

## Functional Measurements

To study renal excretion, mice were placed in metabolic cages for two days on control diet (C1000, Altromin, Lage, Germany) and tap water. Urinary creatinine and serum urea were measured using enzymatic colorimetric creatinine and urea kits (Lehmann, Berlin, Germany), Urinary albumin was measured using a fluorimetric albumin test kit (Progen, PR2005, Heidelberg, Germany) following the manufacturer's instructions. Evaluation of albuminuria (expressed as the albumin to creatinine ratio) was performed as previously described ${ }^{1}$. Plasma concentrations of $\mathrm{Na}^{+}, \mathrm{K}^{+}$and $\mathrm{Ca}^{2+}$ were measured by flame photometry (efux 5057, Eppendorf, Hamburg, Germany). Plasma and urinary magnesium and phosphorus concentration were determined by colorimetric methods (Lehmann, Berlin, Germany).

## Urinary and plasma HPLC measurements

Amino acid concentrations in plasma and urine were determined on Biochrom 30+ amino acid analyzers (Laborservice Onken, Gründau, Germany), using cation exchange chromatography and post-column derivatization with ninhydrin. Prior to injection, samples were deproteinized with sulfosalicylic acid. External control was performed using the ERNDIM quality control scheme (www.erndimqa.nl) "Amino Acids".

## Fixation and tissue processing for immunohistochemistry and immunoblotting

Kidneys were shock-frozen for biochemical evaluation or perfused retrogradely using $4 \%$ PFA in PBS and either postfixed o/n and subsequently transfered into $0.1 \%$ PFA in PBS for
paraffin embedding or processed for electronmicroscopy or transferred into 800 mOsm Sucrose in PBS overnight and subsequently frozen in OCT. Paraffin embedded sections were further processed for PAS-staining. To assess fluid phase and receptor mediated endocytosis HRP (Sigma, Schnelldorf, Germany) was given at a concentration of $120 \mu \mathrm{~g} / \mathrm{g}$ BW and Alexa555 (Invitrogen, Karlsruhe, Germany) labeled B-lactoglobulin (Sigma) at $4 \mu \mathrm{~g} / \mathrm{g}$ BW i.v. into the retroorbital plexus under light isoflurane anesthesia. Kidneys were harvested 5 min later and immediately perfused with 4\% PFA in PBS and processed as described above. For electron microscopy tissue specimens were post-fixed in $1.5 \%$ glutaraldehyde and embedded in Epon 812 (Serva, Heidelberg, Deutschland) followed by contrasting ultrathin sections with osmium and uranylacetate. For isolation of membrane fractions kidneys were homogenized in isolation buffer and processed as described ${ }^{2}$. Total protein concentration was measured using the Pierce BCA Protein Assay reagent kit (Pierce, Schwerte, Germany) and controlled by Coomassie staining.

## SDS-PAGE and Immunoblotting

Proteins were solubilized and SDS gel electrophoresis was performed on 8-10\% polyacrylamide gels. After electrophoretic transfer of the proteins to nitrocellulose membranes, equity in protein loading and blotting was verified by membrane staining using $0.1 \%$ Ponceau red. Membranes were probed with primary antibodies and then exposed to HRP-conjugated secondary antibodies (Dianova, Hamburg, Germany). Immunoreactive bands were detected by chemiluminescence (Amersham Pharmacia, Glattbrugg, Switzerland). Densitometric evaluation was performed by BIO-PROFIL Bio-1D image software (Vilber Lourmat, Eberhardzell, Germany).

## Immunohistochemistry

Cryosections were blocked with $5 \%$ skim milk/PBS, incubated with the respective primary antibody followed by the suitable cy-2 or cy-3-coupled secondary antibody (Dianova). Double-antibody staining procedure was controlled by parallel incubation of consecutive
sections, each probed only with one single antibody. Sections were analyzed using a multilaser confocal scanning microscope (SP5, Leica, Heerbrugg, Switzerland).

## Antibodies

The following antibodies were used: rabbit anti-raptor (24C12), rabbit anti-rictor (53A2), rabbit anti-p70S6K (49D7), rabbit anti-phospho-p70S6K (108D2), rabbit anti-S6P (5G10), rabbit anti-phospho-S6P (D57.2.2E), rabbit anti-4E-BP1 (53H11), rabbit anti-p-4E-BP1 (T37/46, 236B4); all purchased from Cell Signaling Technologies and sheep anti-NDRG1, sheep anti-phospho-NDRG1 (kind gift of D. Alessi, University of Dundee, UK), guinea pig anti-megalin ${ }^{3}$, goat anti-cubilin (Santa Cruz Biotechnology, Heidelberg, Germany, A20), rabbit anti-clathrin (Abcam, Cambridge UK, ab 21679), rabbit- anti $B^{0} A T 1^{4}$, rabbit- anti $y^{+}$LAT1 ${ }^{5}$, 4F2hc (CD98 M-20, Santa Cruz Biotechnology, Heidelberg, Germany), DOCK8 (ab121177 Abcam), BCL-xL (54H6 Cell Signaling Technologies) and Alexa647-coubled phalloidin (ThermoFischer Scientific, Zug, Switzerland).

## Electron microscopic evaluation

Ultrathin sections were analyzed using a transmission electron microscope Philips CM12. Images were taken from transverse sectioned S1 segments near the urinary pole and ultrastructural parameters such as microvilli length, number of microvilli per inner diameter length, number of total endocytic vesicles per cell area, number of early endosomes and late endosomes per cell area and mitochondria per cell area were evaluated morphometrically using Fiji software (1.49k). To avoid evaluation of tangentially sectioned epithelia, parallel alignment of BBM microvilli was used as a criterion. Only patent tubules were examined.

## Cell culture, viral transfection and treatment

Opossum kidney cells (OKC) were kindly provided by H. Murer, University of Zürich, Switzerland. Cells were cultured at $37^{\circ} \mathrm{C}$ in $95 \%$ air/ $5 \%$ CO2 in high-glucose ( $450 \mathrm{mg} / \mathrm{dl}$ ) DMEM supplemented with $5 \%$ fetal bovine serum, penicillin ( $100 \mathrm{U} / \mathrm{ml}$ ), and streptomycin ( $100 \mathrm{\mu g} / \mathrm{ml}$ ). OKC were transduced with recombinant adenovirus expressing shRNA targeting human p70S6K (S6K1) and rictor driven by the U6 promoter (kindly provided by Z. Yang, Fribourg, Switzerland ${ }^{6}$ ). Targeting sequences was in congruent with the respective opossum cDNA sequences. Viral titer was determined by QuickTiter ${ }^{\text {TM }}$ Adenovirus Titer Immunoassay Kit (LuBio Science, Luzern, Switzerland). The control recombinant adenoviruses expressing shRNA targeting LacZ was from Invitrogen life Technologies, Zug, Switzerland. S6K1 targeting sequence: GGACATGGCAGGAGTGTTTGA; Rictor targeting sequence: ACTTGTGAAGAATCGTATCTT. At a confluence of $70-90 \%$ OKC were transduced with the recombinant adenovirus at titers of 100 MOI and cultured in complete medium for 3-5 days. Degree of knockdown was verified by TaqMan of S6K1 mRNA (Hs00177357_m1) compared to the housekeeping mRNA Tata-box binding protein (Mm00446973_m1) and the protein expression by western blot analysis of S6K1 and rictor. In comparison to MOCK transduction, OKC transduced with either S6K1 shRNA alone or S6K1 and rictor shRNA revealed a knockdown of S6K1 mRNA of $-68 \pm 12 \%$ and $-67 \pm 11 \%$, ${ }^{*} p<0.05$ respectively. S6K1 protein expression was reduced by $-69 \pm 15 \%$ and $-63 \pm 12 \%$, respectively. Rictor protein expression was in comparison to MOCK transduction reduced by $-66 \pm 17 \%$ and by $87 \pm 20 \%$ for OKC treated either with rictor shRNA alone or S6K1 and rictor shRNA, respectively.

In the case of endocytosis assay, cells were serum-starved overnight. Confluent OKC were incubated either for 3 days with various mTOR kinase inhibitors or overnight with various concentrations of rapamycin. Additionally, p70S6K specific inhibitor PF-4708671 incubated for $16-18 \mathrm{~h}$ was used. If not otherwise indicated the following concentrations were used; 100 nM rapamycin, 250 nM torin, 100 nM PP242 and $3 \mu \mathrm{M}$ and $10 \mu \mathrm{M}$ PF-4708671 (Sigma

Aldrich) in FCS-free medium. $10 \mu \mathrm{M}$ colchicine (Sigma Aldrich), a microtubule inhibitor, was always used overnight. Subsequently, the endocytosis assay was performed by incubating OKC with $0.1 \mathrm{mg} / \mathrm{ml}$ Alexa647-coupled albumin (Molecular Probes, Zug, Switzerland) for 30 minutes, followed by extensive washing, fixing with $3 \%$ PFA in PBS and flow cytometry measurements. The downstream effects of various concentrations of rapamycin incubated overnight was tested by immunoprecipitation of 4E-BP1 followed by western blot analysis of p-4E-BP1. Afterwards membranes were stripped and revealed with anti-4E-BP1 antibody. The ratios of $\mathrm{p}-4 \mathrm{E}-\mathrm{BP} 1 / 4 \mathrm{E}-\mathrm{BP} 1$ with increasing concentrations of rapamycin were: $0 \mathrm{nM}: 100$ $\pm 31 \%, 5 \mathrm{nM}: 79 \pm 17 \%, 10 \mathrm{nM}: 75 \pm 7 \%, 100 \mathrm{nM} 62 \pm 13 \%$ and $500 \mathrm{nM}: 63 \pm 21 \%$.

## Measurement of lysosomal pH and enzyme activity

The pH of lysosomes was measured with LysoSensor Yellow/Blue DND-160 (Molecular Probes, Zug, Switzerland) according to the manufacturer's protocol. In brief, OKC were collected by trypsin/EDTA and stained with LysoSensor at 1:200 concentrations in standard culture medium for 10 minutes followed by washing with PBS. Fluorescence of cell suspension in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 7.0) was measured by a microtiter plate at excitation $365 \mathrm{~nm} /$ emission 450 nm (for blue) and $485 \mathrm{~nm} /$ emission 550 nm (for yellow). Standard curves were obtained in each sample using pH -fixed MES-buffer ( pH 4.0 - 6.5) with $10 \mu \mathrm{M}$ nigericin (Sigma Aldrich, St. Gallen, Switzerland) and $10 \mu \mathrm{M}$ monensin (Sigma Aldrich).

The activity of lysosomal enzymes was measured by incubating homogenate of virally transduced OK cells with the appropriate substrate. The reaction was allowed to proceed for 30 minutes at $37^{\circ} \mathrm{C}$ and then stopped with 5 mL of 85 mM glycine-carbonate buffer ( pH 10.5). $200 \mu \mathrm{~L}$ of homogenate was incubated with $100 \mu \mathrm{~L}$ of 0.5 mM 4 -methylumbelliferyl (MU)-$\beta$-galactoside in 100 mM citrate-phosphate buffer ( pH 4.35 ) with $0.4 \mathrm{M} \mathrm{NaCl} . \beta$ Glucuronidase was measured by incubating $200 \mu \mathrm{~L}$ of homogenate with of $100 \mu \mathrm{~L}$ of $1 \mathrm{mM} 4-$ MU- $\beta$-d-glucuronide in 100 mM acetate buffer (pH 4.0). $\alpha$-Mannosidase was measured by
incubating $50 \mu \mathrm{~L}$ of homogenate with $100 \mu \mathrm{~L}$ of $4 \mathrm{mM} 4-\mathrm{MU}-\alpha-$ d-mannopyranoside in 100 mM citrate-phosphate buffer ( pH 4.0 ). The substrates were purchased from Sigma Aldrich, St. Gallen, Switzerland. The released 4-MU was measured against blank and standard 4-MU solutions. Fluorescence was determined with a Perkin Elmer 2030 Multilabel Reader Victor X 3 at 450 nm after excitation at 360 nm .

## D. melanogaster nephrocyte model system

D. melanogaster stocks were cultured on standard cornmeal molasses agar food and maintained at $25^{\circ} \mathrm{C}$. RNAi-Based Nephrocyte Functional Screen Procedure: Virgins from MHC-ANF-RFP, HandGFP, and Dot-Gal4 transgenic lines (Gift from Zhe Han, University of Michigan, Ann Arbor, USA) were crossed to UAS-CG8487-RNAi (VDRC TID 42140/GD) males at $25^{\circ} \mathrm{C} ; 2$ days after crossing, flies were transferred to small collection cages with grape juice agar plates to collect the embryos for 24 hours at $25^{\circ} \mathrm{C}$. Collected embryos were aged for 48 hours at $29^{\circ} \mathrm{C}$ and then subjected to examination of the RFP accumulation in pericardial nephrocytes using a confocal microscope. The RFP mean fluorescence intensity of GFP positive areas was measured to quantify the uptake efficiency.

Virgins of prospero-Gal4 (gift from Barry Denholm, University of Edinburgh, Edinburgh, UK) were crossed to UAS-CG8487-RNAi males (VDRC TID 42140/GD) for a GCN-specific knockdown of Gartenzwerg. GCN preparations for TEM were fixed in 4\% PFA and $1 \%$ Glutaraldehyde and embedded in low melting Agarose. Tissue samples were then embedded in epoxy resin (Durcopan, Plano, Germany). Ultrathin sections of 40nm thickness were analyzed using a Zeiss TEM 906 (Zeiss, Oberkochen, Germany).

## Sample preparation for MS/MS

Snap frozen kidney cortex were homogenized on ice and solubilized in 8M cold urea buffer containing 50 mM ammonium bicarbonate and 1 x Protease and phosphatase inhibitor cocktail (Pierce, ThermoFischer Scientific, Rockford, USA). Lysates were cleared with a 20 min spin of 20.000 g in a benchtop centrifuge. Next, the supernatant was recovered and proteins were reduced, alkylated and digested at a $1: 100 \mathrm{w} / \mathrm{w}$ trypsin/total protein ratio as previously described ${ }^{7}$. Protein abundance was measured using a commercial BCA assay (Pierce). 5\% of the digest was retained for proteomic analysis. $800 \mu \mathrm{~g}$ of the remaining peptides was subjected to phosphopeptide enrichment using Fe-NTA immobilized metal affinity chromatography columns (Pierce) without further fractionation as previously described ${ }^{7,8}$. All samples were cleaned up using C18 resin in stage tips as previously described ${ }^{9}$.

## Nano-liquid chromatography and mass spectrometry

The cleaned peptides were separated using nLC on a house-packed 50 cm C18 column in a column oven. The particle size was $1.7 \mu \mathrm{~m}$ C18 beads (Dr Maisch GmbH, AmmerbuchEntringen, Germany). We analyzed the peptides using the following solvent gradient with ascending concentrations of buffer B as compared to buffer A.: $t=0 \mathrm{~min}$; 4\% [Buffer B], 05 min, $6 \%$; 125 min, $23 \%$; $132 \mathrm{~min}, 54 \%$; $138 \mathrm{~min}, 85 \%$; $143 \mathrm{~min}, 85 \%$; $145 \mathrm{~min} 5 \%$ ). Buffer B was $80 \%$ ACN, $0.1 \%$ FA and buffer A was $0.1 \%$ FA. The flow rate was constant with 250 $\mathrm{nl} / \mathrm{min}$. The phosphopeptides were separated using nLC with the following gradient (0min, $10 \%$ [Buffer B]; 5min, 10\%; $125 \mathrm{~min} ; 38 \%$, 132 min 60\%; 138, 95; 143, 95\%; $148 \mathrm{~min} ; 95 \%$ and $148 \mathrm{~min} 5 \%$ ) Peptides were directly sprayed into a quadrupole-orbitrap based mass spectrometer QExactive Plus (Thermo) run in positive ion mode as previously described ${ }^{10}$. The acquisition parameters were as follows: A MS1 precursor scan was followed by 10 MS2 scans of the most intense ions (Top10 method). The resolution was 70000 for MS1 scans and 17500 for MS2 scans. AGC target was 3e6 for MS1 scans, and 5e5 for MS2 scans.

Mass range was 300-1750 m/z for MS1 scans, and 200-2000 m/z for MS2 scans. Isolation window was $2.1 \mathrm{~m} / \mathrm{z}$, dynamic exclusion was enabled (20s).

## Bioinformatic analysis

Raw files were searched using the MaxQuant software package, v 1.5.1.0 ${ }^{11}$, including LFQ algorithm ${ }^{12}$. The raw data were searched against a recent uniprot reference proteome database for mouse including common potential contaminants (Decoy mode: revert). The parameters were mainly default with a few modifications: Carbamidomethylation of cysteins as fixed modification, deisotoping enabled, mass accuracy for first search 20ppm, for second search 4.5 ppm . PSM, protein and site FDR was set to 0.01 , minimal peptide length was 7 , score for unmodified peptides was 0 , and modified was 16. At least one peptide was necessary for protein identification. Variable modifications included N-terminal acetylation and methionine oxidation. In addition, phosphorylation (mass shift approximately +80 ) on STY residue was added as a variable modification for samples enriched for phosphorylated peptides. Match between runs (matching time 0.7 min , matching window 20 min ) and label free quantification was enabled. At least 2 counts were necessary for a ratio. The MaxQuant output .txt files (PhosphoSTY.txt and proteingroups.txt) were then analyzed, visualized and normalized using the Perseus software, v. 1.5.1.0. For LFQ, only 5 missing values were tolerated, and for phosphorylation sites no missing value was tolerated. All other proteins or sites were filtered from the dataset. Two samples, for which identification count and/or MS/MS run was not sufficient (protein identification number less than -1SD from the mean) were removed entirely from the analysis. Missing values were imputed (SD downshift 1.8, width 0.3) after logarithmizing intensities and checking for normal distribution. Hierarchical clustering was performed based on the Euclidean distance. Vulcano plots were generated after a paired two-sample t-test. To determine significantly changed proteins, and to circumvent the multiple testing problem, a statistical approach similar to significance analysis of microarrays (SAM) ${ }^{13}$ was utilized. This approach can also be applied to proteomics data. The threshold for significance was 0.3 after 250 randomizations ( $\mathrm{s} 0=1$ ). Proteins and
phosphorylation sites considered significant were exported and depicted in the respective tables. GO terms, keywords (uniprot) as well as PFAM domains and KEGG pathways were annotated using the Perseus annotation packages. Next, a fishers exact test was performed to assess whether there were special categories overrepresented in the changed protein and site populations as compared to the non-changed entities (for proteins, this test was performed separately for the significantly increased and the significantly decreased proteins). The significantly changed GO terms were reanalyzed and condensed using Revigo ${ }^{14}$ and visualized in Cytoscape ${ }^{15}$. The cumulative histogram was generated using the Prism (Graphpad) software. Phosphorylation motifs of the upregulated or downregulated phosphopeptide population were generated using the phosphologo software ${ }^{16}$. Known phosphosites, known substrates and regulatory sites were added manually to the Table S4. Using a binary decision tree we separated the phosphorylation motifs in "basophilic", "proline-directed", "acidophilic" and "others". ${ }^{17}$

All MS raw files, including search results and metadata, are deposited at the ProteomeXchange repository ${ }^{18}$. Project accession: PXD002422 (http://www.ebi.ac.uk/pride/archive/projects/PXD002422).

## Supplemental Figure Legends

Supplementary Fig. 1. Triple labeling of either mTOR, RAPTOR, S6K1, S6P or NDRG1 (red); megalin (green) and phalloidin to stain actin filaments (blue) on control mouse renal sections. (A) mTOR is localized to the subapical membrane region, ( $A^{\prime}$ ) merged image demonstrating proximal tubular expression. Insert of ( $A^{\prime}$ ) is depicted in ( $A^{\prime \prime}$ ) showing mTOR localized in vicinity to megalin. (B) RAPTOR localizes to vesicles of the subapical membrane region of S1 and S2 portions of the proximal tubule, (B) merged image demonstrating proximal tubular expression. For more detailed analysis insert of $\left(B^{\prime}\right)$ is depicted in ( $\mathrm{B}^{\prime}$ ) presenting a partial overlap between RAPTOR and megalin. (C) S6K1 is found in vesicular structures of the subapical membrane region and throughout the cytoplasm, (C') merged image demonstrating proximal tubular expression. Note, S3 segments marked by an asterisk are devoid of vesicular expression and show only intracellular staining. Insert of $(C)$ is depicted in (C') showing the vesicular structures positive for S6K1 and megalin in the S1 segment. (D) Ribosomal S6 protein (S6P) is found in the apical membrane region of the proximal tubule; (D) merged image is verifying proximal tubular expression. Insert of (D) is depicted in (D') showing ribosomal S6P expression in close vicinity to megalin with occasional overlap. (E) NDRG1 is found to be expressed in the apical membrane region of the convoluted part of the proximal tubule; ( $E^{\prime}$ ) merged image is verifying proximal tubular expression. Asterisk marks the S3 segment of the proximal tubule which lacks a NDRG1 signal. Insert of ( $E^{\prime}$ ) is depicted in ( $E^{\prime \prime}$ ) showing partial coexpression of NDRG1 and megalin. Magnification as indicated by scale bar.

Supplementary Fig. 2. (A) Urinary acidic and basic amino acid excretion of Rap ${ }^{\Delta T u b b u l e}$, Ric $^{\Delta T u b u l e}$ and RapRic ${ }^{\Delta T u b u l e}$. (B) Serum concentration of neutral, acidic and basic amino acids of Rap ${ }^{\text {STubule }}$, Ric ${ }^{\Delta T u b u l e}$ and RapRic ${ }^{\text {STubule }}$. ${ }^{*} P$-value vs. control $<0.05$; ** $P$-value vs. control $<0.01$.

Supplementary Fig.3. Immunohistochemical staining of MEGALIN (A) and CUBILIN (B) on Rap ${ }^{\Delta T u b u l e}$, Ric ${ }^{\Delta T u b u l e}$ and RapRic ${ }^{\text {TTubule }}$ in comparison to their respective control. (C) Western blot analysis of MEGALIN from Rap ${ }^{\Delta T u b u l e}$, Ric ${ }^{\Delta T u b u l e}$ and RapRic ${ }^{\Delta T u b u l e}$. Densitometric analysis of MEGALIN western blots from Rap ${ }^{\Delta T u b u l e}$, Ric ${ }^{\Delta T u b b l e}$ and RapRic ${ }^{\Delta T u b u l e}$. No significant difference in expression intensity or subcellular distribution were observed.

Supplementary Fig. 4. Histological alterations of Rap ${ }^{\Delta T u b u l e}$ and RapRic ${ }^{\Delta T u b u l e} 3$ month after induction. (A) PAS-stained paraffin sections of Con, Rap ${ }^{\text {STubule }}$ and RapRic ${ }^{\text {ATubule }}$. Black stippled line indicates boundary between cortex and outer medulla and yellow stippled line boundary between outer stripe and inner stripe. (B) Expression of MEGALIN from Con, Rap ${ }^{\text {STubule }}$ and RapRic ${ }^{\text {STubule }}$. (C) Expression of CUBILIN from Con, Rap ${ }^{\Delta T u b u l e}$ and RapRic ${ }^{\Delta T u b u l e}$. (D) Expression of $\mathrm{Na}^{+} / \mathrm{K}^{+}$-ATPase (NKA) from Con, Rap ${ }^{\Delta T u b u l e}$ and RapRic ${ }^{\Delta T u b u l e}$. Distal tubules are indicated by an asterisk. Missorting of NKA containing vesicles towards the apical membrane in Rap ${ }^{\Delta T u b u l e}$ and RapRic ${ }^{\Delta T u b u l e}$ and reduced basolateral expression in RapRic ${ }^{\Delta T u b u l e}$ is shown. Magnification as indicated by scale bar.

## Supplementary Fig. 5. Pharmacological inhibition of mTORC1, mTORC1/2 or P70S6K1 and knock-down of mTORC2 and/or P70S6K1-induced signaling in proximal tubule

 cells. (A) Quantitative evaluation of flow cytometrical analysis of endocytosis assay performed in opossum kidney cells (OKC) treated for 3 days with 100 nM rapamycin, 100 nM PP242 and 250 nM torin or overnight with $10 \mu \mathrm{M}$ colchicine. Representative image of flow cytometrical analysis (right). (B) Quantitative evaluation of flow cytometrical analysis of endocytosis assay performed on OKC treated with increasing concentrations of rapamycin or colchicine overnight. Representative image of flow cytometrical analysis (right). (C) Quantitative evaluation of flow cytometrical analysis of endocytosis assay performed on OKC treated with $3 \mu \mathrm{M}$ and $10 \mu \mathrm{M}$ PF-4708671 (PF) and 100 nM rapamycin for $16-18$ hours. Representative image of flow cytometrical analysis (right). (D) Quantitative evaluation of flowcytometrical analysis of endocytosis assay performed on viral transduced OKC with knockdown of S6K1, RICTOR or both proteins. Representative image of flow cytometrical analysis (right). (E) Lysosomal pH of virally transduced OKC with knockdown of S6K1, RICTOR or both proteins. (F) Quantitative assessment of clathrin-coated vesicles per $\mu \mathrm{m}^{3}$ of virally transduced OKC with knockdown of S6K1, RICTOR or both proteins. (G) Representative images of merged z-scans in a 3D illustration are depicted. Scale bar $=40$ $\mu \mathrm{m}$. ${ }^{*} P$-value vs. control $<0.05$; ** $P$-value vs. control $<0.01$; ${ }^{\#} P$-value vs. control $<0.001$.

## Supplemental tables

Supplemental Table 1. Physiological parameters of Con, Rap ${ }^{\Delta T u b u l e}$, Ric ${ }^{\Delta T u b u l e}$ and RapRic ${ }^{\text {©Tubule }}$. All values are rounded means given with min-max and $n$-number. ${ }^{*} P$-value vs. control <0.05; ** $P$-value vs. control $<0.01$.

Supplemental Table 2. Quantitative electron microscopy analysis. Microvilli length, number of microvilli per length cell surface, number of vesicles per cell area and mitochondrial area per cell area given in \% of Rap ${ }^{\Delta T u b u l e}$, Ric $^{\Delta T u b b l e}$ and $R a p R i c^{\Delta T u b u l e}$ in comparison to their respective controls. * $P$-value vs. control $<0.05$; ** $P$-value vs. control $<0.01$; ${ }^{\#} P$-value vs control <0.001.

Supplemental Table 3. Identified proteins with significant changes in expression level of Rap ${ }^{\text {STubule }}$ in comparison to control. (A) Proteins which were significantly increased, (B) proteins which were significantly reduced.

Supplemental Table 4. Identified changes of phosphorylation level of proteins of Rap ${ }^{\Delta T u b u l e}$ in comparison to control. (A) Phosphorylation sites of proteins which were significantly increased, (B) phosphorylation sites of proteins which were significantly reduced. In addition known phosphosites, substrates and regulatory sites are indicated.

## Supplemental Information References

1. Schell, C, Baumhakl, L, Salou, S, Conzelmann, AC, Meyer, C, Helmstadter, M, Wrede, C, Grahammer, F, Eimer, S, Kerjaschki, D, Walz, G, Snapper, S, Huber, TB: N-wasp is required for stabilization of podocyte foot processes. Journal of the American Society of Nephrology : JASN, 24: 713-721, 2013.
2. Gadau, J, Peters, H, Kastner, C, Kuhn, H, Nieminen-Kelha, M, Khadzhynov, D, Kramer, S, Castrop, H, Bachmann, S, Theilig, F: Mechanisms of tubular volume retention in immune-mediated glomerulonephritis. Kidney International, 75: 699-710, 2009.
3. Theilig, F, Kriz, W, Jerichow, T, Schrade, P, Hahnel, B, Willnow, T, Le Hir, M, Bachmann, S: Abrogation of protein uptake through megalin-deficient proximal tubules does not safeguard against tubulointerstitial injury. Journal of the American Society of Nephrology : JASN, 18: 1824-1834, 2007.
4. Romeo, E, Dave, MH, Bacic, D, Ristic, Z, Camargo, SM, Loffing, J, Wagner, CA, Verrey, F: Luminal kidney and intestine SLC6 amino acid transporters of BOAT-cluster and their tissue distribution in Mus musculus. American Journal of Physiology - Renal physiology, 290: F376-383, 2006.
5. Dave, MH, Schulz, N, Zecevic, M, Wagner, CA, Verrey, F: Expression of heteromeric amino acid transporters along the murine intestine. The Journal of Physiology, 558: 597-610, 2004.
6. Xiong, Y, Yepuri, G, Forbiteh, M, Yu, Y, Montani, JP, Yang, Z, Ming, XF: ARG2 impairs endothelial autophagy through regulation of MTOR and PRKAA/AMPK signaling in advanced atherosclerosis. Autophagy, 10: 2223-2238, 2014.
7. Rinschen, MM, Wu, X, Konig, T, Pisitkun, T, Hagmann, H, Pahmeyer, C, Lamkemeyer, T, Kohli, P, Schnell, N, Schermer, B, Dryer, S, Brooks, BR, Beltrao, P, Krueger, M, Brinkkoetter, PT, Benzing, T: Phosphoproteomic analysis reveals regulatory mechanisms at the kidney filtration barrier. JASN, 25: 1509-1522, 2014.
8. Rinschen, MM, Yu, MJ, Wang, G, Boja, ES, Hoffert, JD, Pisitkun, T, Knepper, MA: Quantitative phosphoproteomic analysis reveals vasopressin V2-receptordependent signaling pathways in renal collecting duct cells. PNAS, 107: 38823887, 2010.
9. Rappsilber, J, Ishihama, Y, Mann, M: Stop and go extraction tips for matrixassisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Analytical Chemistry, 75: 663-670, 2003.
10. Nolte, H, Konzer, A, Ruhs, A, Jungblut, B, Braun, T, Kruger, M: Global protein expression profiling of zebrafish organs based on in vivo incorporation of stable isotopes. Journal of Proteome Research, 13: 2162-2174, 2014.
11. Cox, J, Mann, M: MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnology, 26: 1367-1372, 2008.
12. Cox, J, Hein, MY, Luber, CA, Paron, I, Nagaraj, N, Mann, M: Accurate proteomewide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Molecular \& Cellular Proteomics : MCP, 13: 2513-2526, 2014.
13. Tusher, VG, Tibshirani, R, Chu, G: Significance analysis of microarrays applied to the ionizing radiation response. PNAS, 98: 5116-5121, 2001.
14. Supek, F, Bosnjak, M, Skunca, N, Smuc, T: REVIGO summarizes and visualizes long lists of gene ontology terms. PloS One, 6: e21800, 2011.
15. Shannon, P, Markiel, A, Ozier, O, Baliga, NS, Wang, JT, Ramage, D, Amin, N, Schwikowski, B, Ideker, T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research, 13: 24982504, 2003.
16. Douglass, J, Gunaratne, R, Bradford, D, Saeed, F, Hoffert, JD, Steinbach, PJ, Knepper, MA, Pisitkun, T: Identifying protein kinase target preferences using mass spectrometry. American Journal of Physiology Cell Physiology, 303: C715-727, 2012.
17. Villen, J, Beausoleil, SA, Gerber, SA, Gygi, SP: Large-scale phosphorylation analysis of mouse liver. PNAS, 104: 1488-1493, 2007.
18. Vizcaino, JA, Deutsch, EW, Wang, R, Csordas, A, Reisinger, F, Rios, D, Dianes, JA, Sun, Z, Farrah, T, Bandeira, N, Binz, PA, Xenarios, I, Eisenacher, M, Mayer, G, Gatto, L, Campos, A, Chalkley, RJ, Kraus, HJ, Albar, JP, MartinezBartolome, S, Apweiler, R, Omenn, GS, Martens, L, Jones, AR, Hermjakob, H: ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nature Biotechnology, 32: 223-226, 2014.

Supplemental Figure 1


Supplemental Figure 2

A


B




## Supplemental Figure 3




## Supplemental Figure 5



|  | Con | Rap ${ }^{\text {TTubule- }}$ | Ric ${ }^{\text {dTubule }}$ | RapRic ${ }^{\text {STubule }}$ |
| :---: | :---: | :---: | :---: | :---: |
| body weight <br> (g) | $28,9[27,5-30,3],(n=50)$ | 27,7 [25,9-29,5], (n=19) | 25,2 [23,1-27,2], (n=12) | $24,0$ [22,3-25,7] **, ( $n=19)$ |
| food intake (mg/ g body weight) | 99 [91-108], ( $\mathrm{n}=42$ ) | 118 [102-134] *, (n=12) | 109 [98-120], ( $\mathrm{n}=12$ ) | 127 [111-143] **, (n=15) |
| fluid intake ( $\mu \mathrm{l} / \mathrm{g}$ body weight) | 218 [166-270], ( $\mathrm{n}=39$ ) | 675 [458-892] **, ( $\mathrm{n}=12$ ) | 233 [135-331], $(\mathrm{n}=11)$ | 407 [329-484] **, (n=15) |
| serum urea (mg/dl) | 53 [42-64], (n=17) | 62 [47-78], ( $\mathrm{n}=6$ ) | 61 [40-81], $(\mathrm{n}=6)$ | $105[84-126]^{* *},(\mathrm{n}=6)$ |
| urine volume ( $\mu \mathrm{l} / \mathrm{g}$ body weight) | 50 [39-60], ( $\mathrm{n}=42$ ) | 387 [206-568] **, ( $\mathrm{n}=12$ ) | 58 [29-87], ( $\mathrm{n}=12$ ) | 140 [109-172] *, (n=15) |
| urinary sodium ( $\mu \mathrm{mol} / \mathrm{mg}$ crea/ g food) | 148 [134-162], $(\mathrm{n}=41)$ | $195[127-263]$ *, (n=12) | 152 [115-190], ( $\mathrm{n}=12$ ) | $208[173-243]^{* *},(\mathrm{n}=15)$ |
| urinary potassium ( $\mu \mathrm{mol} / \mathrm{mg}$ crea/ g food) | 241 [216-162], $(\mathrm{n}=41)$ | 291 [211-370], $(\mathrm{n}=12)$ | 211 [196-225], ( $\mathrm{n}=12$ ) | 315 [262-368], ( $\mathrm{n}=15$ ) |
| urinary calcium ( $\mu \mathrm{mol} / \mathrm{mg}$ crea/ g food) | 1,5 [1,1-1,8], ( $\mathrm{n}=38$ ) | $2,5[1,4-3,6],(\mathrm{n}=12)$ | 1,0 [0,7-1,4], ( $\mathrm{n}=12$ ) | 1,9 [1,4-2,4], ( $\mathrm{n}=15$ ) |

## Table 2

|  | microvilli lenght in <br> $\mu \mathrm{m}$ | number of <br> microvilli per $\mu \mathrm{m}$ <br> lenght cell surface | Number of <br> vesicles per cell <br> area | Mitochondria in <br> $\%$ |
| :---: | :---: | :---: | :---: | :---: |
| Con | $1.71 \pm 0.23$ | $4.91 \pm 0.41$ | $1.01 \pm 0.14$ | $40.53 \pm 5.13$ |
| Rap $^{\Delta \text { Tubule }}$ | $1.25 \pm 0.04^{\star *}$ | $3.42 \pm 0.49^{\#}$ | $0.71 \pm 0.04^{\star *}$ | $37.42 \pm 2.35$ |
| Con | $1.52 \pm 0.19$ | $5.05 \pm 0.61$ | $1.05 \pm 0.12$ | $41.45 \pm 5.77$ |
| Ric $^{\text {}{ }^{\text {Tubulue }}}$ | $1.31 \pm 0.17^{*}$ | $3.38 \pm 0.65^{\star}$ | $0.83 \pm 0.15^{\star}$ | $37.52 \pm 3.57$ |
| Con | $1.55 \pm 0.16$ | $4.81 \pm 0.44$ | $1.00 \pm 0.12$ | $39.58 \pm 2.71$ |
| RapRic ${ }^{\text {}{ }^{\text {Tubule }}}$ | $1.06 \pm 0.05^{\#}$ | $2.98 \pm 0.17^{\#}$ | $0.58 \pm 0.06^{\#}$ | $32.12 \pm 3.47^{*}$ |

A. Proteins increased in Rap ${ }^{\Delta \text { Tubule }}$ as compared to control
$\left.\begin{array}{lllll}\text { Gene } & & \text { Uniprot } & \text { Protein names } & \mathbf{l o g}_{2} \text { intensity } \\ \text { (Rap/control) }\end{array}\right)$-log(P-value)

| Apoa1 | Q00623 | Apolipoprotein A-I | 1,21 |
| :--- | :--- | :--- | :--- |
| Spink3 | P09036 | Serine protease inhibitor Kazal-type 3 | 1,19 |
| Snrpc | Q62241 | U1 small nuclear ribonucleoprotein C | 1,92 |
| Myg1 | F8WGG3 | UPF0160 protein MYG1, mitochondrial | 2,68 |
| Hamp | Q9EQ21 | Hepcidin | 0,97 |
| Nt5e | Q61503 | 5-nucleotidase | 1,16 |
| Them7 | Q9DCP4 | Novel Thioesterase superfamily domain and Saposin A-type domain contain | 1,13 |
| Eefsec | Q9JHW4 | Selenocysteine-specific elongation factor | 1,13 |
| Man2b1 | O09159 | Lysosomal alpha-mannosidase | 1,12 |
| Fnbp1I | E9PUK3 | Formin-binding protein 1-like | 1,78 |
| N/A | P01843 | Ig lambda-1 chain C region | 1,63 |
| Tpm1 | B7ZNL3 | ropomyosin alpha-1 chain | 1,11 |
| Enpep | P16406 | Glutamyl aminopeptidase | 1,11 |
| Ace2 | Q8R0I0 | Angiotensin-converting enzyme 2 | 1,09 |
| Blvrb | Q923D2 | Flavin reductase (NADPH) | 1,04 |
| Ren1 | P06281 | Renin-1 | 1,04 |
| Fdx1I | Q9CPW2 | Adrenodoxin-like protein, mitochondrial | 1,02 |
| Cpsf6 | Q6NVF9 | Cleavage and polyadenylation specificity factor subunit 6 | 1,01 |

## B. Proteins decreased in Rap ${ }^{\Delta \text { Tubule }}$ as compared to control

| Gene names | Uniprot | Protein names | $\log _{2}$ intensity <br> (Rap/control) | -log(P-value) |
| :---: | :---: | :---: | :---: | :---: |
| Thsd4 | Q3UTY6 | Thrombospondin type-1 domain-containing protein 4 | -2,79 | 0,98 |
| 4933436101 F | F99D3T1 | Protein 4933436101Rik | -2,73 | 1,18 |
| Dock8 | Q8C147 | Dedicator of cytokinesis protein 8 | -2,70 | 0,82 |
| Dnah10 | F7ABZ6 | Protein Dnah10 | -2,50 | 1,89 |
| Slc26a1 | P58735 | Sulfate anion transporter 1 | -2,22 | 1,30 |
| Slc7a7 | Q9Z1K8 | Y+L amino acid transporter 1 | -2,08 | 1,55 |
| Bloc1s5 | Q8R015 | Biogenesis of lysosome-related organelles complex 1 subunit 5 | -1,89 | 0,64 |
| Rtn3 | Q9ES97 | Reticulon-3 | -1,89 | 1,17 |
| Ppp6r1 | Q7TSI3 | Serine/threonine-protein phosphatase 6 regulatory subunit 1 | -1,73 | 2,61 |
| Dnajc12 | Q9R022 | DnaJ homolog subfamily C member 12 | -1,57 | 3,45 |
| Bcl211 | A2AHX9 | Bcl-2-like protein 1 | -1,55 | 1,03 |
| Fbxo22 | D6REV6 | F-box only protein 22 | -1,55 | 2,20 |
| SIc6a19 | D6RJ80 | Sodium-dependent neutral amino acid transporter B(0)AT1 | -1,54 | 1,22 |
| Slc5a12 | Q49B93 | Sodium-coupled monocarboxylate transporter 2 | -1,51 | 4,94 |
| Rab10 | P61027 | Ras-related protein Rab-10 | -1,48 | 1,25 |
| Uros | Q3TPL3 | Uroporphyrinogen-III synthase | -1,44 | 0,82 |
| Cbx1 | P83917 | Chromobox protein homolog 1 | -1,39 | 0,95 |
| Sdc4 | 035988 | Syndecan-4 | -1,39 | 1,39 |
| Cyp51a1 | Q8K0C4 | Lanosterol 14-alpha demethylase | -1,38 | 1,20 |
| Ankrd44 | J3QK13 | Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B | -1,35 | 0,94 |
| Snx8 | Q8CFD4 | Sorting nexin-8 | -1,24 | 1,05 |
| Phgdh | Q61753 | D-3-phosphoglycerate dehydrogenase | -1,21 | 3,57 |
| Mrpl13 | Q9D1P0 | 39S ribosomal protein L13, mitochondrial | -1,20 | 1,26 |
| Larp1 | Z4YJT3 | La-related protein 1 | -1,13 | 1,68 |
| Nccrp1 | G3X9C2 | F-box only protein 50 | -1,12 | 1,06 |
| G6pc | P35576 | Glucose-6-phosphatase | -1,11 | 1,04 |
| Slc16a1 | P53986 | Monocarboxylate transporter 1 | -1,10 | 3,58 |
| Hspa14 | Q99M31 | Heat shock 70 kDa protein 14 | -1,09 | 1,22 |
| Glul | P15105 | Glutamine synthetase | -1,08 | 4,29 |
| Chd4 | E9QAS4 | Chromodomain-helicase-DNA-binding protein 4 | -1,02 | 1,47 |
| Rhot1 | Q8BG51 | Mitochondrial Rho GTPase 1 | -1,00 | 1,45 |
| SIc43a2 | Q8CGA3 | Large neutral amino acids transporter small subunit 4 | -1,00 | 2,96 |
| Rpl6 | P47911 | 60S ribosomal protein L6 | -0,99 | 2,74 |
| Rpl7 | P14148 | 60 r ribosomal protein L7 | -0,93 | 1,79 |
| Rpl26 | P61255 | 60S ribosomal protein L26 | -0,91 | 3,96 |
| Ca14 | Q9WVT6 | Carbonic anhydrase 14 | -0,91 | 2,50 |
| Aacs | Q9D2R0 | Acetoacetyl-CoA synthetase | -0,89 | 4,05 |
| SIc3a2 | P10852 | 4F2 cell-surface antigen heavy chain | -0,88 | 4,26 |
| Rpl19 | A2A547 | 60 ribosomal protein L19 | -0,88 | 2,53 |
| Slc22a8 | 088909 | Solute carrier family 22 member 8 | -0,82 | 3,07 |



